Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers

Abstract

The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.

1 . (canceled) 
     
     
         2 . A method of inhibiting growth of a cell which expresses a 158P1D7 protein, comprising:
 providing to the cell an antibody or antigen binding fragment thereof that specifically binds to the 158P1D7 protein, which comprises the amino acid sequence of SEQ ID NO: 3, wherein the antibody or antigen binding fragment thereof specifically binds to the protein within amino acid residues 25-45 or 274-285 of SEQ ID NO: 3, and wherein the cell expressing the protein is a bladder cell, whereby growth of the cell that expresses the protein is inhibited.   
     
     
         3 . The method of  claim 2 , wherein the antibody or antigen binding fragment thereof specifically binds to the protein within amino acid residues 25-45 of SEQ ID NO: 3. 
     
     
         4 . The method of  claim 2 , wherein the antibody or antigen binding fragment thereof specifically binds to the protein within amino acid residues 274-285 of SEQ ID NO: 3. 
     
     
         5 . The method of  claim 2 , wherein the cell is a cancer cell. 
     
     
         6 . The method of  claim 2 , wherein the antibody fragment is selected from the group consisting of an Fab, F(ab′)2, Fv and sFv. 
     
     
         7 . The method of  claim 2 , wherein the antibody or fragment thereof is labeled with an agent. 
     
     
         8 . The method of  claim 7 , wherein the agent is a diagnostic agent or a cytotoxic agent. 
     
     
         9 . The method of  claim 8 , wherein the cytotoxic agent is selected from the group consisting of radioactive isotopes, chemotherapeutic agents and toxins. 
     
     
         10 . The method of  claim 9 , wherein the radioactive isotope is selected from the group consisting of  211 At,  131 I,  125 I,  90 Y,  186 Re,  188 Re,  153 Sm,  212 Bi,  32 P and radioactive isotopes of Lu. 
     
     
         11 . The method of  claim 9 , wherein the chemotherapeutic agent is selected from the group consisting of taxol, actinomycin, mitomycin, etoposide, teniposide, vincristine, vinblastine, colchicine, gelonin, and calicheamicin. 
     
     
         12 . The method of  claim 9 , wherein the toxin is selected from the group consisting of diphtheria toxin, enomycin, phenomycin, Pseudomonas exotoxin (PE) A, PE40, abrin, abrin A chain, mitogellin, modeccin A chain, and alpha-sarcin. 
     
     
         13 . A method of inhibiting growth of a cancer cell which expresses a 158P1D7 protein, comprising:
 providing to the cell an antibody or antigen binding fragment thereof that specifically binds to the 158P1D7 protein, which comprises the amino acid sequence of SEQ ID NO: 3, wherein the antibody or antigen binding fragment thereof specifically binds to the protein within amino acid residues 25-45 or 274-285 of SEQ ID NO: 3, and wherein the cell expressing the protein is a bladder cancer cell, whereby growth of the cancer cell that expresses the protein is inhibited.   
     
     
         14 . The method of  claim 13 , wherein the antibody or antigen binding fragment thereof specifically binds to the protein within amino acid residues 25-45 of SEQ ID NO: 3. 
     
     
         15 . The method of  claim 13 , wherein the antibody or antigen binding fragment thereof specifically binds to the protein within amino acid residues 274-285 of SEQ ID NO: 3. 
     
     
         16 . The method of  claim 13 , wherein the antibody fragment is selected from the group consisting of an Fab, F(ab′)2, Fv and sFv. 
     
     
         17 . The method of  claim 13 , wherein the antibody or fragment thereof is labeled with a diagnostic agent or a cytotoxic agent. 
     
     
         18 . The method of  claim 17 , wherein the cytotoxic agent is selected from the group consisting of radioactive isotopes, chemotherapeutic agents and toxins. 
     
     
         19 . The method of  claim 18 , wherein the radioactive isotope is selected from the group consisting of  211 At,  131 I,  125 I,  90 Y,  186 Re,  188 Re,  153 Sm,  212 Bi,  32 P and radioactive isotopes of Lu. 
     
     
         20 . The method of  claim 18 , wherein the chemotherapeutic agent is selected from the group consisting of taxol, actinomycin, mitomycin, etoposide, teniposide, vincristine, vinblastine, colchicine, gelonin, and calicheamicin. 
     
     
         21 . The method of  claim 18 , wherein the toxin is selected from the group consisting of diphtheria toxin, enomycin, phenomycin, Pseudomonas exotoxin (PE) A, PE40, abrin, abrin A chain, mitogellin, modeccin A chain, and alpha-sarcin.